Lung CancerNCT06483295
Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform
A study testing Using mobile internet platforms for follow-up management of postoperative symptoms in lung cancer patients. in people with Lung Cancer, run by Shanghai Chest Hospital at 1 site in China.
Trial summary
This study focuses on the significant impact of lung cancer in China, highlighted by its high incidence and mortality rates, influenced by factors like aging populations, smoking, and environmental issues. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Lung Cancer
- What is being tested?
- Using mobile internet platforms for follow-up management of postoperative symptoms in lung cancer patients.
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 216 participants
- Where
- 1 siteChina
- Study dates
- 24 Mar 2024to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosed with Stage I-III lung cancer and surgically resected at our centre.
- Owns and uses a smartphone and can use WeChat.
- Volunteer to participate in this study and sign an informed consent form.
Who cannot join
- Received any non-surgical anti-tumour therapy (radiotherapy, chemotherapy, targeted therapy or immunotherapy) for lung cancer during the follow-up period.
- After enrolment, preoperative emergence of serious comorbidities (inability to tolerate surgery or anaesthesia) that are not suitable for, or cannot be implemented as planned, in the study's treatment regimen.
- After admission, the patient's condition changes and the need to change from elective surgery to emergency surgery is confirmed by the doctor in charge.
- At any stage after entering the study, the patient voluntarily requests to withdraw or discontinue treatment due to personal reasons.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Zuodong Song
Shanghai, Shanghai Municipality, 200030
Zuodong Song, szd1990@hotmail.com
About this study
Official title: Randomized Controlled Study on Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform
This study focuses on the significant impact of lung cancer in China, highlighted by its high incidence and mortality rates, influenced by factors like aging populations, smoking, and environmental issues. It emphasizes the importance of understanding the duration, severity, and factors affecting post-surgery symptoms like pain and coughing in patients. The research underlines the value of patient-reported outcomes (PROs) in enhancing postoperative care and survival rates through improved symptom monitoring and patient engagement. Utilizing internet technology, specifically a platform integrated with WeChat, the study aims to improve patient management and follow-ups post-discharge. The objective is to use mobile internet technology to build a high-quality prospective database on postoperative lung cancer patient outcomes, analyzing factors affecting postoperative discomfort and assessing the role of interactive platforms in improving patient care.
Read the detailed description
Lung cancer is the leading cause of cancer-related deaths worldwide. In China, it has become the malignancy with the highest incidence and mortality rates, exacerbated by aging populations, smoking, and environmental issues. Post-major lung surgery, patients often experience reduced quality of life due to symptoms like pain and coughing. However, the duration, severity, and factors influencing these symptoms during recovery are not fully understood. Notably, recent attention has been given to the direct collection of patient-reported outcomes (PROs) for subjective symptom monitoring and improving patient care. Incorporating PRO monitoring in cancer patient follow-ups can reduce postoperative discomfort, enhance treatment tolerance and adherence, detect early relapses, and improve survival rates. Internet technology significantly expands information exchange frequency and efficiency. Management platforms based on internet mobile applications can enhance patient management compliance, enable intelligent follow-ups, and strengthen doctor-patient interaction. The investigators' hospital intends to utilize its internet hospital platform, integrated with WeChat (a Tencent application in China), for assisting in-patient management and post-discharge surveillance through automated multimedia material and PROs. WeChat, similar to Facebook and WhatsApp, is a multifunctional messenger app with over a billion active monthly users in China, effectively using an application already familiar to patients rather than introducing new ones.
This study aims to leverage mobile internet technology to transform traditional database construction, enhance the efficiency and accuracy of prospective database information collection, and establish a high-quality prospective database of postoperative lung cancer patient-reported outcomes. This will facilitate the analysis of factors influencing postoperative discomfort in patients and explore the role of interactive mobile internet technology platforms in improving postoperative PROs, thereby elevating the diagnostic and treatment standards in this field.
- Conditions
- Lung Cancer
- Being tested
- Using mobile internet platforms for follow-up management of postoperative symptoms in lung cancer patients.
- Keywords
- patient-reported outcomes, Internet
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Using mobile internet platforms for follow-up management of postoperative symptoms in lung cancer patients.Other
Using mobile internet platforms for follow-up management of postoperative symptoms in lung cancer patients.
| Study group | Role | What they receive |
|---|---|---|
| Group A | Experimental | Mobile Internet Platform Follow-up Group Receives: Other: Using mobile internet platforms for follow-up management of postoperative symptoms in lung cancer patients. |
| Group B | No intervention | Traditional Outpatient Follow-up Group |
What is being measured
The primary outcome is the main question the study is designed to answer.
complaints of discomfort
MDASI-LC score for complaints of discomfort at postoperative months 1, 3 and 4
Postoperative discomfort chief complaint MDASI-LC score:
Choose a number from 0 (asymptomatic) to 10 (the most severe level imaginable) for each item to indicate the severity of the symptoms.
The main complaints of postoperative discomfort include: pain, cough, shortness of breath (key points) Other factors include fatigue, nausea, insomnia, depression, memory loss, loss of appetite, drowsiness, dry mouth, sadness, vomiting, numbness or stinging wounds, constipation, etc
Measured: 4 months
Secondary outcomes (4)
Life quality
Quality of life scores at postoperative months 1, 3, and 4
EQ5D scoring table for postoperative quality of life:
Q1: Activity ability A: Walking is not a problem; B: There are some walking problems; C: Bedridden and unable to get up.
Q2: Self care ability A: Can be completely self-care; B: There are some issues with taking a shower or dressing; C: Unable to take a shower or dress on their own.
Q3: Daily activities (such as work, study, household chores, family or leisure activities) A: There is no problem with daily activities; B: There are some issues with daily activities; C: Unable to perform daily activities Q4: Pain/discomfort A: No pain/discomfort; B: Moderate pain/discomfort; C: Extreme pain/discomfort Q5: Anxiety/Depression A: Not anxious/depressed; B: Mild anxiety/depression; C: Moderate anxiety/depression
Measured: 4 months
Pulmonary function-the absolute value of FEV1
Pulmonary function test results comparing different resection styles
Perform lung function tests during the study period, including the absolute value of FEV1, the percentage of FEV1 to expected values, etc
Measured: 4 months
Pulmonary function-the percentage of FEV1 to expected values
Pulmonary function test results comparing different resection styles
Perform lung function tests during the study period, including the absolute value of FEV1, the percentage of FEV1 to expected values, etc
Measured: 4 months
Change of breath sounds
Modelling of breath sounds after resection of different resection styles
By collecting postoperative respiratory sounds from different resection methods, converting the audio into digital signals for analysis, and then modeling and calculating, a large model of postoperative respiratory sounds from different resection methods is established to evaluate the postoperative respiratory sounds of patients.
Measured: 4 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jul 2024
- Study start24 Mar 2024
- Primary completion7 Jul 2024
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- More trials run by Shanghai Chest HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 216 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shanghai Chest Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Xinghua Cheng, Shanghai Chest Hospital
- Investigators
- Xinghua Cheng, MD, Principal investigator, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06483295
- Sponsor's protocol ID
- ShanghaiChestPRO
- Status last verified
- May 2025
- First submitted
- 13 Mar 2024
- Last updated
- 28 May 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Luo Y, Cheng Y, Song Z, Chen H, Bo Y, Shixing H. Patient-reported outcomes with a personalized follow-up program after lung cancer resection: A single-center randomized controlled trial. Asia Pac J Oncol Nurs. 2026 Jan 2;13:100844. doi: 10.1016/j.apjon.2025.100844. eCollection 2026 Dec.
PubMed 41625083
Study at a glance
From the registry record, last updated by the sponsor on 28 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Controlled Study on Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform
- ClinicalTrials.gov ID
- NCT06483295
- Acronym / sponsor ID
- ShanghaiChestPRO
- Conditions
- Lung Cancer
- Keywords
- patient-reported outcomes, Internet
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 216 participants (estimated)
- Lead sponsor
- Shanghai Chest HospitalUniversity, hospital or other
- Study start
- 24 Mar 2024 (actual)
- Primary completion
- 7 Jul 2024 (actual)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 3 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study focuses on the significant impact of lung cancer in China, highlighted by its high incidence and mortality rates, influenced by factors like aging populations, smoking, and environmental issues. It emphasizes the importance of understanding the duration, severity, and factors affecting post-surgery symptoms like pain and coughing in patients. The research underlines the value of patient-reported outcomes (PROs) in enhancing postoperative care and survival rates through improved symptom monitoring and patient engagement. Utilizing internet technology, specifically a platform integrated with WeChat, the study aims to improve patient management and follow-ups post-discharge. The objective is to use mobile internet technology to build a high-quality prospective database on postoperative lung cancer patient outcomes, analyzing factors affecting postoperative discomfort and assessing the role of interactive platforms in improving patient care.
Detailed description
Lung cancer is the leading cause of cancer-related deaths worldwide. In China, it has become the malignancy with the highest incidence and mortality rates, exacerbated by aging populations, smoking, and environmental issues. Post-major lung surgery, patients often experience reduced quality of life due to symptoms like pain and coughing. However, the duration, severity, and factors influencing these symptoms during recovery are not fully understood. Notably, recent attention has been given to the direct collection of patient-reported outcomes (PROs) for subjective symptom monitoring and improving patient care. Incorporating PRO monitoring in cancer patient follow-ups can reduce postoperative discomfort, enhance treatment tolerance and adherence, detect early relapses, and improve survival rates. Internet technology significantly expands information exchange frequency and efficiency. Management platforms based on internet mobile applications can enhance patient management compliance, enable intelligent follow-ups, and strengthen doctor-patient interaction. The investigators' hospital intends to utilize its internet hospital platform, integrated with WeChat (a Tencent application in China), for assisting in-patient management and post-discharge surveillance through automated multimedia material and PROs. WeChat, similar to Facebook and WhatsApp, is a multifunctional messenger app with over a billion active monthly users in China, effectively using an application already familiar to patients rather than introducing new ones.
This study aims to leverage mobile internet technology to transform traditional database construction, enhance the efficiency and accuracy of prospective database information collection, and establish a high-quality prospective database of postoperative lung cancer patient-reported outcomes. This will facilitate the analysis of factors influencing postoperative discomfort in patients and explore the role of interactive mobile internet technology platforms in improving postoperative PROs, thereby elevating the diagnostic and treatment standards in this field.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A | Experimental | Other: Using mobile internet platforms for follow-up management of postoperative symptoms in lung cancer patients.Mobile Internet Platform Follow-up Group |
| Group B | No intervention | –Traditional Outpatient Follow-up Group |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Diagnosed with Stage I-III lung cancer and surgically resected at our centre.
- Owns and uses a smartphone and can use WeChat.
- Volunteer to participate in this study and sign an informed consent form.
Key exclusion criteria (4 listed)
- Received any non-surgical anti-tumour therapy (radiotherapy, chemotherapy, targeted therapy or immunotherapy) for lung cancer during the follow-up period.
- After enrolment, preoperative emergence of serious comorbidities (inability to tolerate surgery or anaesthesia) that are not suitable for, or cannot be implemented as planned, in the study's treatment regimen.
- After admission, the patient's condition changes and the need to change from elective surgery to emergency surgery is confirmed by the doctor in charge.
- At any stage after entering the study, the patient voluntarily requests to withdraw or discontinue treatment due to personal reasons.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Using mobile internet platforms for follow-up management of postoperative symptoms in lung cancer patients.Using mobile internet platforms for follow-up management of postoperative symptoms in lung cancer patients. | Other | Group A |
Primary outcome
complaints of discomfort
Time frame: 4 months
MDASI-LC score for complaints of discomfort at postoperative months 1, 3 and 4 Postoperative discomfort chief complaint MDASI-LC score: Choose a number from 0 (asymptomatic) to 10 (the most severe level imaginable) for each item to indicate the severity of the symptoms. The main complaints of postoperative discomfort include: pain, cough, shortness of breath (key points) Other factors include fatigue, nausea, insomnia, depression, memory loss, loss of appetite, drowsiness, dry mouth, sadness, vomiting, numbness or stinging wounds, constipation, etc
4 secondary outcomes
Life quality
Time frame: 4 months
Pulmonary function-the absolute value of FEV1
Time frame: 4 months
Pulmonary function-the percentage of FEV1 to expected values
Time frame: 4 months
Change of breath sounds
Time frame: 4 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 May 2025.
- Derived from this study: PubMed 41625083Luo Y, Cheng Y, Song Z, Chen H, Bo Y, Shixing H. Patient-reported outcomes with a personalized follow-up program after lung cancer resection: A single-center randomized controlled trial. Asia Pac J Oncol Nurs. 2026 Jan 2;13:100844. doi: 10.1016/j.apjon.2025.100844. eCollection 2026 Dec.
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Xinghua Cheng, MD principal investigator
Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Using mobile internet platforms for follow-up management of postoperative symptoms in lung cancer patients. in people with Lung Cancer, run by Shanghai Chest Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xinghua Cheng, MD (+8617701681215, chengxinghua_001@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
complaints of discomfort (time frame: 4 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06483295, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2025.